New NICE Result: Lorlatinib

BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in adults who have not had an ALK inhibitor (1st line, CROWN indication).

This recommendation is not intended to affect treatment with lorlatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Click here for full details on the NICE website.

Other News from NICE

New NICE Approval: Selpercatinib

BTOG wishes to inform members of a new NICE approval that has been published today.NICE has appraised selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer and BTOG is delighted it has been given a positive recommendation for the...

New NICE Approval: Dabrafenib-Trametinib

BTOG wishes to inform members of a new NICE approval that has been published today. NICE has now reappraised dabrafenib-trametinib for BRAF V600E mutant advanced NSCLC and given a positive recommendation for the submitted indication: 1st line BRAF V600E advanced...

NICE publishes quality standard on tobacco

NICE has published the Tobacco: Treating Dependence quality standard (QS207). BTOG endorses this hugely helpful quality standard which covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not...

NICE tobacco guidelines published

The final NICE guideline on Tobacco: preventing uptake, promoting quitting and treating dependence has been published on the NICE website. You can also find the supporting evidence, tools and resources as well as all the stakeholder comments that were received during...

NICE Impact on Lung Cancer Report – November 2019

The National Institute for Health and Care Excellence’s (NICE) latest impact report on lung cancer was published in November 2019. The impact report brings together NICE recommendations and real-world data to highlight how implementing NICE guidance is making a...